JPWO2020168291A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020168291A5
JPWO2020168291A5 JP2021547336A JP2021547336A JPWO2020168291A5 JP WO2020168291 A5 JPWO2020168291 A5 JP WO2020168291A5 JP 2021547336 A JP2021547336 A JP 2021547336A JP 2021547336 A JP2021547336 A JP 2021547336A JP WO2020168291 A5 JPWO2020168291 A5 JP WO2020168291A5
Authority
JP
Japan
Prior art keywords
ribonucleic acid
sequence
engineered
engineered nuclease
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520428A (ja
JP2022520428A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018432 external-priority patent/WO2020168291A1/en
Publication of JP2022520428A publication Critical patent/JP2022520428A/ja
Publication of JPWO2020168291A5 publication Critical patent/JPWO2020168291A5/ja
Publication of JP2022520428A5 publication Critical patent/JP2022520428A5/ja
Priority to JP2023146414A priority Critical patent/JP7502537B2/ja
Priority to JP2024091759A priority patent/JP2024133476A/ja
Ceased legal-status Critical Current

Links

JP2021547336A 2019-02-14 2020-02-14 Ruvcドメインを有する酵素 Ceased JP2022520428A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023146414A JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素
JP2024091759A JP2024133476A (ja) 2019-02-14 2024-06-05 Ruvcドメインを有する酵素

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962805868P 2019-02-14 2019-02-14
US201962805878P 2019-02-14 2019-02-14
US201962805899P 2019-02-14 2019-02-14
US62/805,878 2019-02-14
US62/805,868 2019-02-14
US62/805,899 2019-02-14
US201962874414P 2019-07-15 2019-07-15
US62/874,414 2019-07-15
PCT/US2020/018432 WO2020168291A1 (en) 2019-02-14 2020-02-14 Enzymes with ruvc domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023146414A Division JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素

Publications (3)

Publication Number Publication Date
JP2022520428A JP2022520428A (ja) 2022-03-30
JPWO2020168291A5 true JPWO2020168291A5 (https=) 2023-02-21
JP2022520428A5 JP2022520428A5 (https=) 2023-02-21

Family

ID=72045639

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021547336A Ceased JP2022520428A (ja) 2019-02-14 2020-02-14 Ruvcドメインを有する酵素
JP2023146414A Active JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素
JP2024091759A Pending JP2024133476A (ja) 2019-02-14 2024-06-05 Ruvcドメインを有する酵素

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023146414A Active JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素
JP2024091759A Pending JP2024133476A (ja) 2019-02-14 2024-06-05 Ruvcドメインを有する酵素

Country Status (9)

Country Link
US (1) US20240117330A1 (https=)
EP (1) EP3924482A4 (https=)
JP (3) JP2022520428A (https=)
KR (2) KR102623312B1 (https=)
CN (2) CN113728098A (https=)
AU (3) AU2020223370B2 (https=)
CA (2) CA3130135C (https=)
MX (2) MX2021009886A (https=)
WO (1) WO2020168291A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
AU2020223370B2 (en) * 2019-02-14 2023-04-20 Metagenomi Therapeutics, Inc. Enzymes with RuvC domains
GB2594339B (en) * 2020-02-14 2023-02-08 Metagenomi Inc Enzymes with RUVC domains
GB2617658B (en) 2020-03-06 2024-04-17 Metagenomi Inc Class II, type V CRISPR systems
GB2608292B (en) * 2020-03-31 2024-02-14 Metagenomi Inc Class II, type II CRISPR systems
EP4165177A4 (en) * 2020-05-08 2024-08-28 Metagenomi, Inc. ENZYMES WITH RUVC DOMAINS
KR20230021657A (ko) * 2020-05-08 2023-02-14 메타지노미, 인크. Ruvc 도메인을 포함하는 효소
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
GB2700205B (en) * 2020-09-11 2026-04-15 Metagenomi Therapeutics Inc Base editing enzymes
US20230383273A1 (en) * 2020-10-21 2023-11-30 Emendobio Inc. Novel omni 56, 58, 65, 68, 71, 75, 78, and 84 crispr nucleases
WO2022098681A2 (en) * 2020-11-03 2022-05-12 Caspr Biotech Corporation Novel class 2 crispr-cas rna-guided endonucleases
WO2022159742A1 (en) * 2021-01-22 2022-07-28 Metagenomi, Inc Novel engineered and chimeric nucleases
BR112023014719A2 (pt) * 2021-01-22 2023-12-05 Metagenomi Inc Novas nucleases quiméricas e manipuladas
BR112023018948A2 (pt) * 2021-03-19 2023-10-17 Metagenomi Inc Edição multiplex com enzimas cas
WO2022232638A2 (en) * 2021-04-30 2022-11-03 Metagenomi, Inc. Enzymes with ruvc domains
CA3225082A1 (en) * 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
AU2022380842A1 (en) 2021-11-05 2024-05-23 Metagenomi Therapeutics, Inc. Base editing enzymes
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
WO2023122663A2 (en) * 2021-12-23 2023-06-29 Mammoth Biosciences, Inc. Effector proteins and methods of use
WO2023194359A1 (en) * 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
CN119923466A (zh) * 2022-06-15 2025-05-02 比姆医疗股份有限公司 用于减少补体激活的组合物和方法
US20260014279A1 (en) * 2022-09-16 2026-01-15 Alia Therapeutics Srl Enqp type cas proteins and applications thereof
KR20250153814A (ko) * 2023-03-01 2025-10-27 메타지노미, 인크. Ruvc 도메인을 갖는 효소
WO2025106934A1 (en) * 2023-11-16 2025-05-22 Metagenomi, Inc. Enzymes with ruvc domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894684A1 (en) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
EP3303634B1 (en) * 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US12431216B2 (en) * 2016-08-17 2025-09-30 Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
KR20200124702A (ko) * 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
AU2020223370B2 (en) 2019-02-14 2023-04-20 Metagenomi Therapeutics, Inc. Enzymes with RuvC domains

Similar Documents

Publication Publication Date Title
JPWO2020168291A5 (https=)
US20230123754A1 (en) RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
JPWO2021202568A5 (https=)
O'Connell Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR–Cas systems
JP6986509B2 (ja) 核酸ガイド化ヌクレアーゼをベースとした系を使用する核酸の捕捉
KR102168489B1 (ko) CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도
GB2605340A (en) Base editing enzymes
Sampson et al. Exploiting CRISPR/C as systems for biotechnology
GB2612458A (en) Enzymes with RuvC domains
Emadzade et al. Differential amplification of satellite PaB6 in chromosomally hypervariable Prospero autumnale complex (Hyacinthaceae)
JP2019524149A5 (https=)
CN106554969A (zh) 基于抑菌杀菌的多靶点CRISPR/Cas9表达载体
JP2016537028A5 (https=)
JP2020506667A5 (https=)
JP2018537955A5 (https=)
JP2018534950A5 (https=)
JP2012525849A5 (https=)
JP2016502858A5 (https=)
RU2022103641A (ru) Искусственная модификация генома для регуляции экспрессии гена
JPWO2022056324A5 (https=)
KR20220124652A (ko) CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도
JPWO2023039378A5 (https=)
CN106282173B (zh) 克隆转基因生物中外源基因整合位点处侧翼序列的方法
JPWO2020149395A5 (https=)
Haruta et al. A DNA pairing-enhanced conformation of bacterial RecA proteins